文献支持AMG-208 是一种口服有效的，选择性 c-Met/RON 双抑制剂，对 c-Met 的 IC50 为 9 nM。AMG-208 是一种 CYP3A4 抑制剂，IC50 为 32 μM。AMG-208 具有抗癌活性。

价格： ￥1200

品牌：medchemexpress(MCE)

货号：HY-12035

产品详情

AMG-208

AMG-208 是一种口服有效的，选择性 c-Met/RON 双抑制剂，对 c-Met 的 IC₅₀ 为 9 nM。AMG-208 是一种 CYP3A4 抑制剂，IC₅₀ 为 32 μM。AMG-208 具有抗癌活性。

美国medchemexpress（MCE)浙江省一级代理:杭州昊鑫生物科技股份有限公司
MCE中国是全球领先的科研化学品和生物活性化合物供应商，总部位于美国新泽西。我们的产品范围覆盖各种抑制剂、激动剂、API和化合物库。专业、高效的企业灵魂铸造了在行业的卓越地位。热情和充满活力的研发团队拥有着大量的化学和生物科学家。专注于生物活性化合物，拥有着多年的发展历程和丰富的行业经验。从产品的HNMR数据解析到生物活性数据，从客户的询价到产品的售后服务，我们拥有着完善的管理体系，从而保证我们的服务更加高效、准确。努力为中国的医药行业发展注入新的活力，我们将成为您研发工作值得信赖的伙伴。

生物活性
AMG-208 is an orally active c-Met/RON dual selective inhibitor with an IC50 of 9 nM for c-Met. AMG-208 is a CYP3A4 inhibitor with an IC50 of 32 μM. AMG-208 has anti-cancer activity。

体外研究(In Vitro)
AMG-208 (compound 4) treatment also leads to the inhibition of HGF-mediated c-Met phosphorylation in PC3 cells with IC50 of 46 nM[1].
Pre-incubation of AMG-208 (compound 1) with human liver microsomes for 30 minutes shows a potent time-dependent inhibition for CYP3A4 metabolic activity with IC50 of 4.1 μM, which is an eightfold decrease relative to the IC50 (32 μM) without preincubation[2].

体内研究(In Vivo)
In male Sprague Dawley rats, AMG-208 (0.5 mg/kg i.v.) shows a high bioavailability with Cl of 0.37 L/h/kg, Vss of 0.38 L/kg and T1/2 of 1 hour[1].

分子量
383.40

性状
Solid

Formula
C22H17N5O2

CAS 号
1002304-34-8

运输条件
Room temperature in continental US; may vary elsewhere.

储存方式
Powder   -20°C   3 years
4°C   2 years
In solvent   -80°C   6 months
-20°C   1 month
溶解性数据
In Vitro:
DMSO : 3.33 mg/mL (8.69 mM; Need ultrasonic)

配制储备液
浓度溶剂体积质量   1 mg   5 mg   10 mg
1 mM   2.6082 mL   13.0412 mL   26.0824 mL
5 mM   0.5216 mL   2.6082 mL   5.2165 mL
10 mM   ---   ---   ---
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

参考文献	[1]. Albrecht BK, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem. 2008, 51(10), 2879-2882. [Content Brief] [2]. Boezio AA, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 2009, 19(22), 6307-6312. [Content Brief] [3]. Liu X, et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010,16(1), 37-45. [Content Brief]

参考文献

[1]. Albrecht BK, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem. 2008, 51(10), 2879-2882.  [Content Brief]

[2]. Boezio AA, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 2009, 19(22), 6307-6312.  [Content Brief]

[3]. Liu X, et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010,16(1), 37-45.  [Content Brief]

参考文献	[1]. Albrecht BK, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem. 2008, 51(10), 2879-2882. [Content Brief] [2]. Boezio AA, et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett. 2009, 19(22), 6307-6312. [Content Brief] [3]. Liu X, et al. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010,16(1), 37-45. [Content Brief]